Studies propose that specific targeting pro-inflammatory cytokines produced abundantly, including IL-8, IP-10, and MCP-1, with anti-inflammatory medications holds promise for mitigating influenza-associated inflammation. The gene discussed is CCL2; the disease is influenza.